Allarity Therapeutics, Inc. (ALLR) - מזומנים למניה אחת

Competition in the AI diagnostics niche and pressure from tech giants are driving volatility in share prices, and the GURU.Markets platform displays this cash per share chart for the stock, where the metric level stands at 1.50. The fundamentals of Allarity Therapeutics (ALLR) rely on the DRP system for RNA-based therapy selection, yet a liquidity shortage and the threat of delisting create critical risks for business development.
פילוחי מדדים מקיפים ואנליטיקה עבור Allarity Therapeutics (ALLR)

Developing personalized cancer treatment methods requires significant investment, making the level of liquid assets per share a critical indicator of resilience for Allarity Therapeutics (ALLR). This metric determines the real value of a single security based on available cash reserves. The calculation is based on dividing the total cash volume by the number of shares outstanding. A high ratio guarantees financial viability while conducting costly clinical trials. This allows an investor to objectively compare market capitalization with the company's actual capital.